Becton, Dickinson and Company $BDX Shares Acquired by Massachusetts Financial Services Co. MA

by · The Cerbat Gem

Massachusetts Financial Services Co. MA raised its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 7.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,150,584 shares of the medical instruments supplier’s stock after acquiring an additional 636,138 shares during the quarter. Massachusetts Financial Services Co. MA owned 3.19% of Becton, Dickinson and Company worth $1,712,715,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in BDX. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. RiverGlades Family Offices LLC acquired a new position in shares of Becton, Dickinson and Company in the second quarter worth $344,000. Covea Finance raised its holdings in shares of Becton, Dickinson and Company by 10.7% during the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock worth $14,758,000 after acquiring an additional 7,610 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in Becton, Dickinson and Company during the second quarter valued at $983,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in Becton, Dickinson and Company by 2.0% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 905,757 shares of the medical instruments supplier’s stock valued at $169,531,000 after purchasing an additional 17,844 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 2,662 shares of company stock valued at $535,246. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Bank of America boosted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Finally, Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $207.64.

Get Our Latest Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Down 0.6%

Becton, Dickinson and Company stock opened at $207.16 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a fifty day moving average price of $195.88 and a two-hundred day moving average price of $189.39. The firm has a market cap of $59.02 billion, a price-to-earnings ratio of 35.53, a P/E/G ratio of 2.29 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.92 by $0.04. The company had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the business posted $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.0%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).